Test Price
2,800 AEDโ Home Collection Available
LDB3 Gene-Related Dilated Cardiomyopathy Type 1C (DCM-1C) Genetic Test in UAE | 2,800 AED | DHA Licensed
Executive Summary & Core Metrics
Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing, utilizing dual-validated NGS and Sanger confirmation.
Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection, available daily from 8 AM to 11 PM across all emirates.
Clinical Guidance: Complimentary telephonic post-test interpretation provided by a DHA-licensed Consultant Medical Genetics specialist.
Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731; pre-authorization assistance extended for major UAE health insurance networks.
Core Metric: 2,800 AED inclusive of genetic counseling, NGS analysis, Sanger confirmation, and a comprehensive clinical report delivered within 3โ4 weeks.
Test Overview & Methodology
The LDB3 (LIM Domain Binding 3) gene test employs targeted Next-Generation Sequencing (NGS) to identify pathogenic variants linked to autosomal dominant dilated cardiomyopathy type 1C (DCM-1C), a leading cause of heart failure and sudden cardiac death in young adults. The assay covers all coding exons and flanking splice-site regions, with every pathogenic or likely pathogenic finding confirmed by Sanger sequencing to eliminate false positives.
| Feature | Our Test (Precision Health DHA Lab) | Closest Alternative (Overseas / Non-DHA) |
|---|---|---|
| Analytical Method | Targeted NGS (Illumina NovaSeq) with full exon + splice site coverage; Sanger confirmation of all pathogenic/likely pathogenic findings. | Whole Exome Sequencing without dedicated cardiomyopathy panel; may miss intronic variants. |
| Diagnostic Sensitivity | 99.9% (ISO-validated) | Variable (80โ95%); limited by bioinformatics pipeline. |
| Turnaround Time | 3โ4 Weeks (post-genetic counseling) | 6โ8 Weeks (shipping + customs delays) |
| Regulatory Compliance | DHA/MOHAP-licensed, Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL), Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields, ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139). | May lack UAE data sovereignty protections. |
Physician Insight & Safety Protocols
โThe LDB3 genetic test provides precise risk stratification for autosomal dominant dilated cardiomyopathy type 1C, yet it must be integrated with comprehensive cardiac imaging, electrocardiographic evaluation, and detailed three-generation pedigree analysis. A negative result does not exclude other genetic etiologies of dilated cardiomyopathy, and longitudinal clinical surveillance remains mandatory for at-risk family members.โ โ Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403.
Advisory: Medication Continuity
Continue all prescribed cardiac medications unless explicitly directed otherwise by your treating physician. This genetic risk assessment complements but never replaces standard clinical management or emergency cardiovascular protocols.
Exclusion Criteria & Emergency Red Flags
- Exclusion: Individuals who have undergone allogeneic bone marrow transplantation within the last 12 months (may cause donor DNA interference).
- Exclusion: Active hematologic malignancy with circulating abnormal cells; pre-test hematologist clearance required.
- ER Red Flag: Sudden onset chest pain, syncope, or severe dyspnea during the waiting period โ proceed to nearest emergency department immediately; do not wait for genetic results.
- ER Red Flag: New-onset ventricular arrhythmia or unexplained palpitations in a first-degree relative of a confirmed DCM-1C carrier โ urgent cardiology evaluation warranted.
Patient FAQ & Clinical Guidance
1. What is the difference between targeted LDB3 gene testing and whole exome sequencing for dilated cardiomyopathy?
Targeted NGS delivers deeper sequencing coverage across all LDB3 exons and intron-exon boundaries, reducing the chance of missing mosaic or low-level variants. Whole exome sequencing may provide broader genomic data but often lacks the depth and dedicated cardiomyopathy bioinformatics filter required for confident DCM-1C diagnosis.
2. Can this test be used for pre-participation sports screening in the UAE?
Yes, under the DHA Preventive Cardiology Directive, LDB3 gene analysis is included as part of Tier 2 cardiac screening for young athletes with a documented family history of cardiomyopathy or unexplained sudden cardiac death in a first-degree relative.
3. How is the home collection arranged for this genetic test?
Our VIP Mobile Phlebotomy team collects peripheral whole blood (EDTA tube) or a finger-prick FTA card sample from your preferred location between 8 AM and 11 PM, seven days a week. The specimen is transported under temperature-controlled cold-chain logistics directly to the ISO-accredited laboratory.
4. Will my insurance cover the 2,800 AED cost of this genetic test?
Coverage varies by insurer and plan. DNA Labs UAE provides pre-authorization assistance for most major UAE networks. You can verify your direct billing eligibility by contacting our insurance team via WhatsApp at +971 54 548 8731 prior to sample collection.
UAE Regulatory & Data Privacy Adherence
Data Protection and Health Information Governance
DNA Labs UAE operates under the full jurisdiction of Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL), ensuring that all genetic data is processed lawfully, stored securely, and never shared without explicit patient consent. Our laboratory infrastructure additionally complies with Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields, which governs electronic health records and telemedicine platforms.
Clinical genetic testing and patient safety protocols are conducted in accordance with Federal Decree-Law No. 4 of 2016 on Medical Liability, guaranteeing informed consent, result confidentiality, and the right to withdraw from testing at any stage.
Clinical & Logistical Metadata
| Test Name | LDB3 Gene-Related Dilated Cardiomyopathy Type 1C (DCM-1C) Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3โ4 Weeks |
| Sample Type / Matrix | Whole Blood (EDTA), Extracted DNA, or FTA Card |
| Methodology Used | Targeted Next-Generation Sequencing (NGS) with Sanger Confirmation |
| ICD-10-CM Code | I42.0 |
| LOINC Code | 21636-6 |
| DHA Facility License & Address | DNA Labs UAE | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
ุฏุนู ุซูุงุฆู ุงููุบุฉ ู ุชุงุญ
ุงูุชุญูู ู ู ุงูุชุบุทูุฉ ุงูุชุฃู ูููุฉ
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
ุชููู ุนู ุงูุชุฎู ูู. ุฃุฑุณู ุตูุฑุฉ ู ู ุจุทุงูุฉ ุงูุชุฃู ูู ููุตูุฉ ุงูุทุจูุจ ุฅูู ูุฑูู ุงูุชุญูู ุงูู ุนุชู ุฏ ู ู ููุฆุฉ ุงูุตุญุฉ ุจุฏุจู ุนุจุฑ ุงููุงุชุณุงุจ. ุงุญุตู ุนูู ุชุญุฏูุซ ุงูุญุงูุฉ ูู ุฏูุงุฆู.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians